The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Wiley online. Library. 2018;68:394–424.

Google Scholar 

Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma J Hepatol [internet]. Elsevier; 2018;69:182–236. Available from: https://doi.org/10.1016/j.jhep.2018.03.019.

Galle PR, Dufour J-F, Peck-Radosavljevic M, Trojan J, Vogel A. Systemic therapy of advanced hepatocellular carcinoma. Futur Oncol Future Medicine. 2021;17:1237–51.

CAS  Article  Google Scholar 

Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for hepatocellular carcinoma: a guide for Hepatologists. United States: Hepatology; 2022.

Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in Unresectable hepatocellular carcinoma. N Engl J med [internet]. Massachusetts medical society; 2020;382:1894–1905. Available from: https://doi.org/10.1056/NEJMoa1915745.

Cheng A-L, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73. https://doi.org/10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.

Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol Elsevier. 2022;76:681–93.

Article  Google Scholar 

Foerster F, Galle PR. The current landscape of clinical trials for systemic treatment of hcc Cancers (Basel). Multidisciplinary Digital Publishing Institute. 2021;13:1962.

CAS  Google Scholar 

Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. Nature Publishing Group; 2021;1–22.

Yavuz BG, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, et al. Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma Dove Press. 2021;8:1195.

Article  Google Scholar 

Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy–development and validation of the CRAFITY score. J Hepatol. Elsevier. 2022;76:353–63.

CAS  Article  Google Scholar 

Kuzuya T, Kawabe N, Hashimoto S, Miyahara R, Sawaki A, Nakano T, et al. Early changes in alpha-fetoprotein are a useful predictor of efficacy of Atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma. Oncol Karger Publishers. 2022;100:12–21.

CAS  Google Scholar 

Heinemann V, Stintzing S, Modest DP, Giessen-Jung C, Michl M, Mansmann UR. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer Elsevier. 2015;51:1927–36.

Article  Google Scholar 

Masaki C, Sugino K, Saito N, Saito Y, Tanaka T, Ogimi Y, et al. Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma. Endocr J The Japan Endocrine Society. 2017:EJ17–0104.

Osumi H, Takahari D, Shinozaki E, Chin K, Ogura M, Wakatsuki T, et al. Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer. Gastric Cancer Springer. 2018;21:267–75.

Article  Google Scholar 

Miyake H, Miyazaki A, Imai S, Harada K, Fujisawa M. Early tumor shrinkage under treatment with first-line tyrosine kinase inhibitors as a predictor of overall survival in patients with metastatic renal cell carcinoma: a retrospective multi-institutional study in Japan. Target Oncol Springer. 2016;11:175–82.

Article  Google Scholar 

Almansour H, Afat S, Serna-Higuita LM, Amaral T, Schraag A, Peisen F, et al. Early tumor size reduction of at least 10% at the first follow-up computed tomography can predict survival in the setting of advanced melanoma and immunotherapy. Acad Radiol: Elsevier; 2021.

Google Scholar 

Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A, Sorich MJ. Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab. J Immunother Cancer. 2020;8(1):e000500. https://doi.org/10.1136/jitc-2019-000500.

Kawachi H, Fujimoto D, Morimoto T, Hosoya K, Sato Y, Kogo M, et al. Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using nivolumab. Invest New Drugs Springer. 2019;37:1257–65.

CAS  Article  Google Scholar 

Takahashi A, Moriguchi M, Seko Y, Shima T, Mitsumoto Y, Takashima H, et al. Early tumor shrinkage as a predictive factor for outcomes in hepatocellular carcinoma patients treated with lenvatinib: a multicenter analysis. Cancers (Basel) Multidisciplinary Digital Publishing Institute. 2020;12:754.

CAS  Article  Google Scholar 

Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, et al. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. Cancer Imaging BioMed Central. 2022;22:1–13.

Article  Google Scholar 

Koh D-M. Imaging tumour response: beyond RECIST. Cancer Imaging Springer. 2014;14:1–2.

Google Scholar 

Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) the TRIPOD statement. Circulation Am Heart Assoc. 2015;131:211–9.

Google Scholar 

Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, et al. Immunonutritive scoring in patients with hepatocellular carcinoma undergoing Transarterial chemoembolization: prognostic nutritional index or controlling nutritional status score? Front Oncol. Frontiers. 2021;11:2205.

Google Scholar 

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin liver dis. © Thieme Medical Publishers. 2010:52–60.

Vicentin I, Mosconi C, Garanzini E, Sposito C, Serenari M, Buscemi V, et al. Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. Eur Radiol Springer. 2021;31:8903–12.

Article  Google Scholar 

Choi MH, Park GE, Oh SN, Park MY, Rha SE, Lee YJ, et al. Reproducibility of mRECIST in measurement and response assessment for hepatocellular carcinoma treated by transarterial chemoembolization. Acad Radiol Elsevier. 2018;25:1363–73.

Article  Google Scholar 

Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, et al. Evaluation of HCC response to locoregional therapy: validation of MRI-based response criteria versus explant pathology. J Hepatol. Elsevier. 2017;67:1213–21.

Article  Google Scholar 

Tovoli F, Renzulli M, Negrini G, Brocchi S, Ferrarini A, Andreone A, et al. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. Eur Radiol. Springer. 2018;28:3611–20.

Article  Google Scholar 

Bettinger D, Gkika E, Schultheiss M, Glaser N, Lange S, Maruschke L, et al. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. BMC Cancer Springer. 2018;18:1–9.

Google Scholar 

Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–29. https://doi.org/10.1111/liv.14223.

Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73. https://doi.org/10.1016/j.jhep.2021.11.030.

Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(suppl 4):379. https://doi.org/10.1200/JCO.2022.40.4_suppl.379.

Ipsen. Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer [Internet]. JUNE 28, 2021. [cited 2022 Mar 1]. Available from: https://www.ipsen.com/press-releases/exelixis-and-ipsen-announce-cabozantinib-in-combination-with-an-immune-checkpoint-inhibitor-significantly-improved-progression-free-survival-in-phase-3-cosmic-312-pivotal-trial-in-patients-with-previo/

Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature Nature Publishing Group. 2021;592:450–6.

CAS  Google Scholar 

Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Fontanals LT, et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut. BMJ Publishing Group; 2022.

Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med Nature Publishing Group. 2016;22:1342–50.

CAS  Article  Google Scholar 

Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. Impact Journals, LLC; 2019;10:4018.

Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother cancer Springer. 2019;7:1–7.

CAS  Google Scholar 

Haber PK, Torres-Martin M, Dufour J-F, Verslype C, Marquardt J, Galle PR, et al. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Wolters Kluwer. Health. 2021.

Granito A, Facciorusso A, Sacco R, Bartalena L, Mosconi C, Cea UV, et al. TRANS-TACE: prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma. J Pers Med. MDPI. 2021;11:1041.

Article  Google Scholar 

Salem R, Li D, Sommer N, Hernandez S, Verret W, Ding B, et al. Characterization of response to atezolizumab+ bevacizumab versus sorafenib for hepatocellular carcinoma: results from the IMbrave150 trial. Cancer Med Wiley Online Library. 2021;10:5437–47.

CAS  Google Scholar 

Abd El Aziz MA, Facciorusso A, Nayfeh T, Saadi S, Elnaggar M, Cotsoglou C, et al. Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Vaccines. MDPI. 2020;8:616.

CAS  Article  Google Scholar 

Li J, Wang J, Lei L, Yuan G, He S. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. Eur Radiol. Springer. 2019;29:6519–28.

Article  Google Scholar 

留言 (0)

沒有登入
gif